PMID: 41930299

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Cazzaniga M E, Cogliati V, Rossi E, Paris I, Borella F, Moretti G, Garrone O, Pistelli M, Palumbo R, Ferro A

ESMO real world data and digital oncology · 2026

Vol. 11, pp. 100665

View on PubMedDOI

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.